Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TFPI2 divergent transcript (TFPI2-DT) is a long non-coding RNA identified at the human genome locus associated with the TFPI2 gene. Unlike the well-characterized TFPI2 protein, which is a secreted Kunitz-type serine protease inhibitor and has established roles in tumor suppression, extracellular matrix remodeling, and diseases like cancer and thrombosis[1][5], the TFPI2-DT transcript does not code for protein and its biological or pathological significance is currently unclear in the scientific literature. The entry "TFPI2-DT" can be mistaken for the TFPI2 protein and should be referenced carefully[3]. Summary of Key Issues: - The term "TFPI2 divergent transcript" refers to a non-coding RNA with limited to no functional characterization. - Most published research and clinical relevance pertains to the protein-coding gene TFPI2, not TFPI2-DT. - It is not an established drug target and should not be conflated with TFPI2 protein in structured drug target databases[3].
Not applicable; no known drugs or molecules with mechanism of action targeting TFPI2-DT.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TFPI2 divergent transcript (TFPI2-DT).